Studies of 25-hydroxyvitamin D3-24-hydroxylase (CYP24A1) have demonstrated that it is a bifunctional enzyme capable of the 24-hydroxylation of 1␣,25-(OH) 2D3, leading to the excretory form, calcitroic acid, and 23-hydroxylation, culminating in 1␣,25-(OH) 2D3-26,23-lactone. The degree to which CYP24A1 performs either 23-or 24-hydroxylation is species-dependent. In this paper, we show that the human enzyme that predominantly 24-hydroxylates its substrate differs from the opossum enzyme that 23-hydroxylates it at only a limited number of amino acid residues. Mutagenesis of the human form at a single substrate-binding residue (A326G) dramatically changes the regioselectivity of the enzyme from a 24-hydroxylase to a 23-hydroxylase, whereas other modifications have no effect. Ala-326 is located in the I-helix, close to the terminus of the docked 25-hydroxylated side chain in a CYP24A1 homology model, a result that we interpret indicates that substitution of a glycine at 326 provides extra space for the side chain of the substrate to move deeper into the pocket and place it in a optimal stereochemical position for 23-hydroxylation. We discuss the physiological ramifications of these results for species possessing the A326G substitution, as well as implications for optimal vitamin D analog design. (Fig. 1). Studies using CYP24A1-knockout (8) and VDR-knockout mice (8, 9) demonstrate the total absence of calcitroic acid and 1␣,25-(OH) 2 D 3 -26,23-lactone formation when the vitamin Dinducible, VDR-mediated CYP24A1 is not expressed. The in vivo result of CYP24A1 ablation is decreased viability, with 50% of mice not surviving beyond weaning because of hypercalcemia and nephrocalcinosis (8, 10). Although it has been well established that calcitroic acid is the major biliary product of 1␣,25-(OH) 2 D 3 in the rat (11, 12), there have been claims that intermediates of the C24 oxidation pathway retain some biological activity (13) and that the terminal product of 23-hydroxylation, namely 1␣,25-(OH) 2 D 3 -26,23-lactone, belongs to a family of potent VDR antagonists with potential for use in the treatment of Paget's disease (14, 15).The degree to which CYP24A1 performs either of these pathways varies with the species. It had been shown in the mid-1980s by using isolated kidney mitochondria from a variety of species, that the 24-hydroxylase and 23-hydroxylase activities copurify (16). Although both pathways are used in humans, certain species, such as the guinea pig (17, 18), were shown to 23-hydroxylate, whereas other species, such as the rat, primarily 24-hydroxylate the substrate, 25-OH-D 3 (16). These studies suggested that the two enzyme activities might have different kinetic parameters, but it was not clear whether the activities resided on a single or distinct polypeptide chains. With the cloning and expression of the recombinant protein from different species (19,20), it became clear that a single polypeptide chain was capable of both C23-and C24-hydroxylation activities (5-7).Recent studies of rat and human CYP24A1 hav...